Therapeutic food composition and method to diminish blood sugar fluctuations.
Abstract
A therapeutic food composition for treatment of diabetic patients to diminish fluctuations in blood sugar levels and prevent hypoglycemic episodes, comprising per unit about 20-50 grams of nutrients including a slowly absorbed or digested complex carbohydrate, preferably cornstarch; a more rapidly absorbed complex carbohydrate; protein; and fat, but substantially no simple sugars. Diabetic patients may be treated to diminish blood sugar fluctuations and prevent hypoglycemia via the administration of the novel food composition as an evening or pre-bedtime snack or during the daytime hours to patients receiving insulin therapy or engaging in activities that might provoke hypoglycemia.
Term
Term ended
Expired 3 December 2016, 9.8 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
13 claims: 5 independent, 8 dependent
- 1REIVINDICACIONES :1. Una composición alimenticia terapéutica para tratamiento de pacientes diabéticos para disminuir las fluctuaciones en los niveles de azúcar en la sangre e impedir episodios hipoglicémicos, que comprende por ración o unidad de aproximadamente 20 a 50 gramos de elementos nutritivos, incluyendo: a) de aproximadamente 5 a 15 gramos de carbohidrato complejo absorbido lentamente;b) de aproximadamente 7 a 19 gramos de carbohidrato complejo absorbido rápidamente;c) de aproximadamente 5 a 20 gramos de proteina;y d) de aproximadamente 3 a 7 gramos de grasa.
- 2Una composición de conformidad con la reivindicación 1, con un contenido total de carbohidrato de aproximadamente 17 a 24 gramos.
- 3Una composición de conformidad con la reivindicación 1, en donde el carbohidrato lentamente absorbido es almidón de maíz.
- 4Una composición de conformidad con la reivindicación 3, en donde el almidón de maíz no está cocido. -2222
- 5Una composición de conformidad con la reivindicación 3, que comprende aproximadamente 5 gramos de almidón de maiz por unidad.
- 6Una composición de conformidad con la 5 reivindicación 1, en donde por lo menos una tercera parte de la grasa es grasa monoinsaturada.
- 7Una composición alimenticia terapéutica para tratamiento de pacientes diabéticos para disminuir las fluctuaciones en los niveles de azúcar en la sangre y para 10 impedir episodios hipoglicémicos, la composición proporciona por ración o unidad de aproximadamente 115 a 230 calorías de las cuales:a) de aproximadamente 50 por ciento a 70 por ciento son de carbohidratos complejos absorbidos lentamente 15 y absorbidos rápidamente;b) de aproximadamente 15 por ciento a 25 por ciento son de proteína;y c) de aproximadamente 15 por ciento a 20 por ciento son de grasa. 20
- 8Una composición de conformidad con las reivindicaciones 1 o 7 en la forma de un bocadillo en forma de una barra, budín, galleta, barquillo o batido de leche.
- 9Una composición de conformidad con la reivindicación 8, en la forma de un bocadillo en barra. -2323
- 10Una composición de conformidad con la reivindicación 9, en donde la barra se produce con estrías, perforaciones o ranuras en la misma para división fácil en fracciones de una unidad. reivindicación 1 o 7, en donde los carbohidratos absorbidos rápidamente a la proteína y la grasa se proporcionan mediante polidextrosa, cacahuates, derivados de cacahuate u otras nueces o derivados de nueces.
- 1113. Una composición de conformidad con la reivindicación 1 o 7, en donde la proteína se proporciona mediante proteína de soya, proteína de suero o hidrolizado de caseína.
- 1214. Una método para tratar a un paciente diabético para disminuir las fluctuaciones en los niveles de azúcar en la sangre e impedir episodios hipoglicémicos, el método consiste de la administración al paciente de una composición alimenticia terapéutica que comprende por reación o unidad de aproximadamente 20 a 50 gramos de elementos nutritivos incluyendo:a) carbohidrato complejo lentamente absorbido;b) carbohidrato complejo rápidamente absorbido;-2424 reivindicación 17, en donde el almidón de maíz no está cocido. -2525
- 1319. Un método de conformidad con la reivindicación 17, en donde la composición comprende aproximadamente 5 gramos de almidón de maíz por unidad. forma de un bocadillo en barra, budín, galleta, barquillo o batido de leche. estrías, perforaciones o ranuras en la misma para división reivindicación 14, en donde la composición se administra al -2626 paciente como un bocadillo para la noche o antes de la hora de acostarse. reivindicación 14, en donde adolescente. -2727
Independent claims13
196 paragraphs in 7 sections, as filed
Pf'T 'WORLD INTELLECTUAL PROPERTY ORGANIZATION * International Bureau -
INTERNATIONAL APPLICATION PUBUSHED UNDER THE PATENT COOPERATION TREATY (PCT)
<td>(SI) International Patent Clneelllcation ®: A23L 1 / 29,1 / 09,1 / 0522,1 / 305, 1/30, A61K 31/715</td><td>To the</td><td colspan="2">(11) International PubUcation Number: WO 96/31129 (43) InternaUonal PubUcation Date; October 10, 1996 (10.10.96)</td>
<td colspan="3">(21) Interaatioaal Applicatioo Number: PCT / US95 / 10803 (22) International Filing Date: 25 Auguat 1995 (25.08.95) (30) Priority Data: 08 / 418,210 7 April 1995 (07.04.95) US (71) Applicant: CHILDREN'S HOSPITAL OF LOS ANGELES (US / US); 4650 Sunset Boulevard, Los Angeles, CA 900540700 (US). (72) Inventor: KAUFMAN, Ftancine; 1401 North Bundy Drive, Les Angeles. CA 90049 (US). (74) Agent: SCHIFFMILLER, Martin, W .; Kinchstein, Ottinger, Israel & Schiffmiller, PC. 5S1 Fifth Avenue, New York, NY 10176-0024 (US).</td><td>(81) Designated States: AM. AT. AU. BB, BG, BR, BY, CA, CH. CN. CZ. DE, DK, EE, ES. Fl, GB. GE, HU, JP. KE, KG. KP. KR. KZ, LK. LR. LT. LU. LV, MD. MG. MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ. TT, UA, UZ, VN. ARIPO patent (KE, MW, SD. SZ, UG), European patent (AT, BE, CH, DE, DK. ES, FR, GB, OR, IE, IT, LU. MC, NL, PT, SE), OAPI patent (BF. BJ, CF, CG, CI, CM. GA, GN. ML. MR, NE, SN, TD, TG). PubUshtd With interttationai search repon. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</td>
<td colspan="4">(54) Tltle: THERAPEUTIC FOOD COMPOSITION AND METHOD TO DIMINISH BLOOD SUGAR FLUCTUATIONS (57) Cuddle A thempeutic food composition for treatment of diabetic patients to diminiah fluctuationi in blood lugar levels and prevent hypoglycemic epiaodes, comprising per unit about 20-50 grama of nutrients including a slowly absorbed or digested eomplex earbohydrate, preferebly comrtarch; a more rapidly absorbed eomplex earbohydrate; protect and fot, but aubatantially no simple tugan. Diabetic patients may be treated to diminiah blood tugar fluctuationa and preven! hypoglycemia via the administration of the novel food composition as an evening or pte-bedtime snaclc or during the daytime houn to patients receiving insult therapy or engaging in acdvities that might provoke hypoglycemia.</td>
-1 THERAPEUTIC FOOD COMPOSITION AND METHOD FOR
DECREASE THE FLUCTUATIONS OF SUGAR IN THE BLOOD
REFERENCE TO THE RELATED APPLICATION
This application is a continuation in part of Copending Application Serial Number 08 / 213,542, filed on March 15, 1994.
This invention relates to therapeutic treatments for diabetes mellitus. More particularly, this invention relates to treatment methods and compositions for the prevention of serious fluctuations in blood sugar levels in diabetic patients.
The symptoms of hypoglycemia fall into two main categories. The rapid release of epinephrine causes breathing, tremor, tachycardia, anxiety, and hunger. Central nervous system symptoms include vertigo, headache, blurred vision, dull mental acuity, confusion, abnormal behavior, seizures, and unconsciousness. When hypoglycemia is recurrent or severe, nervous system symptoms predominate and the epinephrine phase may not be recognizable. With faster falls or wide swings in plasma glucose (as in insulin reactions), adrenergic symptoms predominate (Harrison's Principles of Internal Medicine, 11th Edition, McGraw-Hill Book Company, New York, 1987, page 1800).
Numerous strategies have been developed to achieve the goal of maintaining blood glucose at a relatively constant level in diabetic patients, such as open continuous subcutaneous insulin pumps and multiple daily insulin injections. These intense insulin regimens are coupled with home glucose monitoring, and many patients measure their blood glucose levels by finger biting up to 6 to 8 times per day to ensure they stay close to normal blood sugar levels. This regimen is prescribed because studies have shown that by avoiding excessively high blood sugar levels, the long-term outcome of patients with diabetes can be improved. However, this regimen that decreases episodes of high blood sugar content also causes patients to experience lower blood sugar reactions (hypoglycemia).
The results of the Diabetes Complication and Control Trial indicate that intense insulin treatment, even when it significantly slows and reduces retinal, nephrological and neuropathic disease in the long term, leads to a three to ninefold increase in hypoglycemic events, most which occur at night (LY Dawson, Clinical Diabetes, 11: 88-96,
1993). Sometimes these hypoglycemic episodes are serious and can lead to unconsciousness and seizures. Serious hypoglycemic events appear to occur more frequently during the night while the patient is asleep rather than during the day.
When awake, diabetic patients may feel hypoglycemic reactions start and can treat themselves with sugar, in order to bring blood sugar levels back to the normal scale. When they are asleep, patients do not have this knowledge, therefore, the risk of hypoglycemia is much higher during this time.
There is a need to develop strategies to decrease hypoglycemia while continuing to manage diabetes intensively. Corn starch has been used effectively to combat hypoglycemia associated with glycogen storage type 1 disease, a disease that has an inherited absence or deficiency of glucose-6-phosphatase activity in the liver, kidneys and intestines, leading to the accumulation of glycogen in those organs and hypoglycemia during fasting. Protection against low blood sugar content was provided for 6 to 8 hours after ingestion of uncooked corn starch (JI Wolfsdorf et al. Am. J. Clin. Nutr., 51: 1051-7, 1990 ). However, the dosage of the cornstarch used for this treatment was 1.75 grams per kilogram of body weight. This dosage is much higher than can be tolerated by a patient with diabetes mellitus.
Another study has also been carried out in patients with diabetes, providing corn starch during the patient's hospital stay, with a reduction in the nadir of the level of glucose in the blood. The children fasted and then were provided with the full carbohydrate content of the normal snack at bedtime (30 grams carbohydrate) as uncooked corn starch (MT Ververs et al., Eur. J. Clin. Nutr. 47: 258-73, 1983). However, in this study, cornstarch did little to prevent hypoglycemia, and the researchers did not evaluate variable dosages to determine maximum efficacy.
Thus, there is a need for a better method of treating hypoglycemia in both Type I and Type II diabetics. In particular, a treatment or maintenance method is required which will prevent serious hypoglycemic episodes while not causing hyperglycernia.
Blood glucose levels in patients with diabetes mellitus are regulated and stabilized by ingesting a therapeutic food composition that includes a slowly metabolized complex carbohydrate, preferably uncooked corn starch, a more rapidly metabolized complex carbohydrate, protein and fat. The food composition is slowly absorbed from the gastrointestinal tract and maintains relatively stable blood sugar levels in the diabetic patient for up to nine hours.
The food composition, which may be in the form of a snack bar, is preferably administered to diabetic patients shortly before bedtime, and is effective in essentially preventing hypoglycemic night episodes, while not causing hyperglycemia. .
The present invention relates to a therapeutic food composition intended for administration to patients suffering from Type I or Type II diabetes to help maintain proper blood glucose regulation, and to prevent wide fluctuations therein, viz. , hypoglycemic and hyperglycemic episodes. The therapeutic composition should be administered as part of a total treatment program, including diet control and administration of insulin and / or other medications in appropriate cases.
The novel food composition comprises as its essential components:
a) a complex carbohydrate that is slowly absorbed from the human gastrointestinal tract (hereafter slowly absorbed carbohydrate), that is, is slowly digested and is not fully metabolized even after 3 to 4 hours;
b) a complex carbohydrate that is absorbed more quickly from the · digestive tract (then rapidly absorbed carbohydrate);
c) a protein; and
d) a fat.
As used herein, the term "complex carbohydrates" refers to macromolecular carbohydrates including starches, polydextrose, and other polysaccharides.
The therapeutic composition containing the aforementioned components can be in any conventional form of snack, eg, bars, puddings, cookies, wafers, milk shakes and the like. Sandwich type bars that resemble confectionery or granola bars are very convenient for storage, handling, and administration purposes and, when produced with ridges, punctures, or grooves therein, can be easily divided for administration purposes. fraction of a bar when appropriate.
The preferred novel food composition contains from about 20 to about 50 grams of nutritional elements per serving or unit, eg, per bar, including:
* about 17 to 24 grams of total carbohydrates (about 5 to 15 grams of the slowly absorbed carbohydrate and about 7 to 19 grams of the rapidly absorbed carbohydrate);
* about 5 to 20 grams of protein; and * approximately 3 to 7 grams of fat, preferably at least one-third monounsaturated fat.
The term nutritional elements as used herein, refers to carbohydrates, proteins, and fats.
The therapeutic food compositions of the invention preferably provide from about 115 to 230 calories per serving or unit of which:
* about 50 to 70 percent are from slowly absorbed and rapidly absorbed complex carbohydrates;
* about 15 to 25 percent are protein; and * about 15 to 25 percent is fat.
In a preferred embodiment of the invention, the novel food composition is in the form of a bar that includes 17 to 24 grams of total carbohydrate or the equivalent of one to one and a half bread exchanges in a normal diabetic diet plan. The bar contains about 5 to 15 grams of slowly absorbed carbohydrate in the form of uncooked corn starch, which generally comprises a weight of approximately 27 percent amylose and 73 percent amylopectin. The preferred embodiment also contains from about 7 to 19 grams of rapidly absorbed complex carbohydrate, but essentially no simple sugars; approximately 5 to 20 grams of protein; and about 3 to Ί grams of fat, at least a third as monounsaturated fat.
The ingredients in the therapeutic food composition may include any of the conventional food ingredients of adequate purity and health that preferably supply the aforementioned amounts of total calories and the percentage of calories from carbohydrates, protein and fat, respectively, and in where the relative weight scales of slowly absorbed carbohydrates, rapidly absorbed carbohydrates, protein and fat are as stated above. In the preferred embodiment of a snack type bar, ingredients may include, by way of illustration, uncooked cornstarch as the slowly absorbed carbohydrate; polydextrose, peanuts, peanut derivatives (eg, peanut butter), other nuts, or nut derivatives as sources of rapidly absorbed carbohydrates, fat, and protein; and other protein sources such as soy protein, whey protein, and a casein hydrolyzate. Artificial sweeteners or sugar substitutes (eg, aspartame or sorbitol) can be included in the food composition, but no simple sugars, such as
-1010 sucrose. Coloring agents, water, salt, preserving agents and other normal ingredients or additives that are normally used in the preparation of a snack in a candy type bar, can also be used as long as the total nutritional element and the calorie profile of the finished bar or other form of the novel food composition falls within the previously defined parameters.
Uncooked cornstarch is the preferred source of slowly absorbed carbohydrate for the purposes of the invention, since its carbohydrate content and metabolism rate are known and relatively uniform and can easily be formulated into a variety of tasty food compositions.
Many diabetics routinely consume a bedtime snack that contains approximately 30 grams of carbohydrate, often in the form of bread, cereal, or milk. By the treatment method of the present invention, patients suffering from diabetes mellitus are administered from or as part of their normal nighttime snack or before bedtime (in accordance with their recommended bread and protein exchanges), one or two servings or units of the therapeutic food composition, for example, one to two bars prepared in accordance with the invention. The
-1111 number of units administered, including fractions of a unit (such as half bars), will depend on the age, weight and condition of the patient, whether or not the patient takes insulin or other anti-diabetic medication and the blood sugar profile in the patient's normal blood, as determined by blood glucose levels with a sting on the finger or other means of administering blood sugar. The goal of treatment is to prevent blood glucose levels from falling to less than 60 milligrams per deciliter, which is defined as hypoglycemia, while not rising to more than 250 milligrams per deciliter, which is defined as hyperglycemia.
Dosage amounts of less than one unit can be used in younger pediatric patients or in patients who have demonstrated a relatively small tendency to nocturnal hypoglycemic events.
Food compositions prepared in accordance with the invention and administered as described herein have been found in clinical studies with diabetic children and adolescents to be effective in maintaining blood sugar levels within the normal range of 60 milliligrams per deciliter to 250 milligrams per deciliter for as long as 8 to 9 hours or more after ingestion.
-1212
Patients taking insulin to facilitate post-prandial glucose absorption can also be treated during the day with pre-measured doses of the novel food composition, which will be slowly metabolized into monosaccharide glucose over a period of 6 to 8 hours, instead of receiving simple carbohydrates, such as orange juice or other sources of sugar that tend to cause a rapidly crest or peak in the level of glucose in the blood.
During the hours that they are up, the patient's use of the glucose requirement is therefore varied and depends on the level and type of activity, eg, vigorous exercise. The exact amount and frequency of the actual dose will therefore vary from patient to patient and from day to day. In a blood glucose test, which is usually administered as a finger bite to obtain a blood sample, it can be used to monitor daily glucose levels as well as the patient's own subjective experience of the symptoms associated with initiation hypoglycemia. Therefore, in the practice of this invention, a sufficient amount of the complex carbohydrate is administered in the form of the novel food composition to maintain the blood glucose level somewhat above this level, nominally of
-1313 approximately 60 milligrams per deciliter in an average patient.
It will be appreciated by persons skilled in the medical field, generally, and in the administration of diabetic patients specifically, that the composition and method of the present invention are valuable adjuncts to the administration of the conventional diet and drug or therapy. insulin and can provide an easily administered and accepted modality to avoid excessive peaks and valleys in blood glucose levels, particularly the serious hypoglycemic episodes that are experienced by many diabetics.
The following are illustrative examples of the novel composition and method of the present invention.
These examples, however, are not intended to provide ingredients, specific formulations, production methods, or dosage regimens that should be used exclusively to practice the present invention.
EXAMPLE 1
Bar Containing Corn Starch
A therapeutic food composition according to the invention was prepared in the form of
-1414 a sandwich type vanilla nut bar. The bar weighed a total of 31 grams and contained sorbitol, cornstarch, soy protein isolate, peanut butter, water, polydextrose, peanuts, a whey protein concentrate, natural flavors,
<td colspan="2">lecithin and citric acid.</td><td rowspan="2">the bar</td><td colspan="2" rowspan="2">provided</td><td rowspan="2"> 120</td>
<td></td><td>Nutritionally,</td>
<td>calories</td><td>(equivalent to</td><td>an exchange</td><td>of</td><td>bread of</td><td>the</td>
<td>which</td><td>approximately</td><td>the 54 by</td><td colspan="2">hundred were</td><td>of</td>
<td colspan="3">carbohydrates, 23 percent protein</td><td>and 23</td><td>percent</td><td>of</td>
<td>grease.</td><td colspan="2">The bar included 7 grams</td><td>of</td><td>protein</td><td>and</td>
about 3 grams of total fat: about 0.5 gram of saturated fat, 1 gram of polyunsaturated fat and 1 gram of monounsaturated fat.
The total carbohydrate content of the bar was 17 grams of which 5 grams were cornstarch (uncooked) and approximately 12 grams was the most rapidly absorbed carbohydrate which is mainly provided by polydextrose and peanuts.
The bar contained 95 milligrams of sodium and 40 milligrams of potassium.
EXAMPLE 2
Treatment of Diabetic Patients
-1515
The bar of Example 1 was administered to eight diabetic children who had previously experienced episodes of nocturnal hypoglycemia. Each child consumed one bar as part of their regular night snack for 3-5 consecutive nights, and each patient's blood glucose levels were measured multiple times during the night and in the morning upon awakening.
As indicated by the data reported in Table 1, only one patient exhibited hypoglycemia after consuming the therapeutic bar and only on a blood sugar reading of more than a dozen taken from that patient, with hypoglycemia being defined as blood glucose levels of <60 milligrams per deciliter. In contrast, patients all had previously experienced moderate to severe episodes of nighttime hypoglycemia after consuming their regular non-cornstarch nighttime snacks.
TABLE 1
Blood Glucose Reading (milligram / deciliter)
Patient 1:
Day 12 3 4 5
68 340 188 221 172
65
-1616
6
103
116
165
175
204
236
248
203
177
197
169
141
161
149
115
169
139
Patient
Day
3
8 :
2
74
82
94
82
4
165
78
182 125
172 163
Patient 3;
Day 1
0
144
219 256
101
-1717
201
<td colspan="2"> 2</td><td> 146</td><td> 226</td><td> 153</td><td> 106</td><td> 88</td>
<td></td><td> 3</td><td> 176</td><td></td><td></td><td></td><td></td>
<td></td><td> 4</td><td> 96 .</td><td> 101</td><td> 180</td><td> 87</td><td> 93</td>
<td> 5</td><td> 5</td><td> 74</td><td></td><td></td><td></td><td></td>
<td></td><td> 6</td><td> 98</td><td> 131</td><td> 155</td><td> 86</td><td> 85</td>
<td></td><td> 7</td><td> 92</td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td> 114</td><td> 211</td><td> 279</td><td> 114</td><td> 142</td>
<td> 10</td><td>Patient</td><td> 4 :</td><td></td><td></td><td></td><td></td>
<td></td><td>Day</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td></td><td> 0</td><td> 160</td><td> 144</td><td> 88</td><td> 96</td><td> 144</td>
<td></td><td> 1</td><td> 102</td><td></td><td></td><td></td><td></td>
<td> 15</td><td> 2</td><td> 100</td><td> 95</td><td> 66</td><td> 206</td><td> 228</td>
<td></td><td> 3</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 4</td><td> 97</td><td> 50</td><td> 83</td><td> 265</td><td> 146</td>
<td></td><td> 5</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 6</td><td> 105</td><td></td><td></td><td></td><td></td>
<td> 20</td><td> 7</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td> 122</td><td> 153</td><td> 72</td><td> 203</td><td> 84</td>
-1818
Patient 5:
<td>Day</td><td> 1</td><td> 2</td>
<td> 0</td><td> 53</td><td> 154</td>
<td> 1</td><td> 164</td><td> 122</td>
<td> 2</td><td> 128</td><td> 157</td>
<td> 3</td><td> 146</td><td> 158</td>
<td> 4</td><td> 124</td><td> 156</td>
<td> 5</td><td> 116</td><td> 157</td>
<td> 6</td><td> 102</td><td> 156</td>
<td> 7</td><td> 108</td><td> 160</td>
<td> 8</td><td> 118</td><td> 167</td>
<td>Patient</td><td> 6:</td><td></td>
<td>Day</td><td> 1</td><td> 2</td>
<td> 0</td><td> 52</td><td> 129</td>
<td> 1</td><td></td><td></td>
<td> 2</td><td></td><td></td>
<td> 3</td><td> 106</td><td> 83</td>
<td> 4</td><td></td><td></td>
<td> 5</td><td></td><td></td>
<td> 6</td><td> 97</td><td> 132</td>
<td> 7</td><td></td><td></td>
<td> 8</td><td> 124</td><td> 175</td>
<td> 3</td><td> 4</td><td> 5</td>
<td> 99</td><td> 117</td><td> 68</td>
<td> 138</td><td> 199</td><td> 85</td>
<td> 148</td><td> 194</td><td> 103</td>
<td> 175</td><td> 175</td><td> 86</td>
<td> 122</td><td> 124</td><td> 116</td>
<td> 131</td><td> 140</td><td> 165</td>
<td> 105</td><td> 139</td><td> 175</td>
<td> 107</td><td> 132</td><td> 204</td>
<td> 110</td><td> 149</td><td> 285</td>
212
188
179
-1919
Patient
Day
Patient
Day
7:
134
177
196
8:
320
269
282
175
115
132
160
327
387
322
242
132
169
365
264
228
223
205
-2020
The unique formulation of the novel food composition slowly mixed and rapidly absorbed carbohydrates, protein and fat, allowing gradual absorption hydrolysis of complex carbohydrates and maintaining stable blood sugar level for up to eight to nine hours, decreasing hypoglycemia in diabetic patients after a post-prandial period.
Therefore, it has been shown that compositions and methods are provided that achieve the various objects of the invention and that they are well adapted to meet the conditions of practical use.
Since various possible embodiments may be made of the foregoing invention, and since various changes may be made in the embodiments noted above, it will be understood that the matters described herein are to be construed as illustrative and not in a sense of limitation.
What is claimed as new and that you want to protect by means of the patent is indicated in the following claims.
-2121
Contents7
43 members in 16 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 41821095 | United States of America | A | |
| 41821095 | United States of America | A | |
| 418210 | – | – | – |
| US19950418210 | – | – | – |
Members43
| Document | Office | Kind | |
|---|---|---|---|
| IL112967D0 | Israel | D0 | |
| CA2185425A1 | Canada | A1 | |
| WO9524906A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU1993395A | Australia | A | |
| ZA952124B | South Africa | B | |
| IL115470D0 | Israel | D0 | |
| ZA957800B | South Africa | B | |
| CA2191714A1 | Canada | A1 | |
| WO9631129A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU3372895A | Australia | A | |
| EP0750504A1 | European Patent Office (EPO) | A1 | |
| FI964884A | Finland | A | |
| US5605893A | United States of America | A | |
| EP0765126A1 | European Patent Office (EPO) | A1 | |
| CN1152254A | China | A | |
| BR9507944A | Brazil | A | |
| BR9507066A | Brazil | A | |
| AR001286A1 | Argentina | A1 | |
| JPH09512792A | Japan | A | |
| AU690654B2 | Australia | B2 | |
| CA2269334A1 | Canada | A1 | |
| WO9817286A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU5085298A | Australia | A | |
| MX9606068AThis record | Mexico | A | |
| NZ292038A | New Zealand | A | |
| US5843921A | United States of America | A | |
| JPH11500625A | Japan | A | |
| EP0952838A1 | European Patent Office (EPO) | A1 | |
| IL129467D0 | Israel | D0 | |
| AU718692B2 | Australia | B2 | |
| IL115470A | Israel | A | |
| EP0952838A4 | European Patent Office (EPO) | A4 | |
| AU732727B2 | Australia | B2 | |
| US6339076B1 | United States of America | B1 | |
| CA2191714C | Canada | C | |
| EP0765126B1 | European Patent Office (EPO) | B1 | |
| AT216564T | Austria | T | |
| ATE216564T1 | Austria | T1 | |
| DE69526501D1 | Germany | D1 | |
| EP0750504B1 | European Patent Office (EPO) | B1 | |
| DE69527137D1 | Germany | D1 | |
| JP3589673B2 | Japan | B2 | |
| CA2269334C | Canada | C |
Numbers
- Publication, DOCDB
- 9606068
- Publication, EPODOC
- MX9606068
- Application
- 9606068
- Application, DOCDB
- 9606068
- Application, EPODOC
- MX19960006068
Titles2
- English
- THERAPEUTIC FOOD COMPOSITION AND METHOD TO DIMINISH BLOOD SUGAR FLUCTUATIONS.
- Spanish
- COMPOSICION ALIMENTICIA TERAPEUTICA Y METODO PARA DISMINUIR LAS FLUCTACIONES DE AZUCAR EN LA SANGRE.
Classification
- CPC, 18
- A23G3/368
- A21D2/16
- A21D2/186
- A21D2/26
- A23V2002/00
- A61K31/715
- Y10S426/808
- A23L29/212
- A23L7/126
- A23L9/12
- A23L33/40
- A23L33/10
- A23L33/115
- A23L33/17
- A23L25/30
- A61P3/08
- A61P7/00
- A61P3/10
- IPC, 19
- A21D2 16
- A21D2 18
- A21D2 26
- A23G3 00
- A23G3 36
- A23L1 0522
- A61K38 28
- A23L1 164
- A23L1 30
- A23L1 305
- A23L9 10
- A23L25 00
- A23L29 20
- A23L33 00
- A61K31 70
- A61K31 715
- A61P3 08
- A61P3 10
- A61P7 00